nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Ifosfamide—testicular cancer	0.469	0.529	CiPCiCtD
Temozolomide—Alkylating Activity—Chlorambucil—testicular cancer	0.418	0.471	CiPCiCtD
Temozolomide—CYP3A4—Ifosfamide—testicular cancer	0.00777	0.428	CbGbCtD
Temozolomide—CYP3A4—Vinblastine—testicular cancer	0.00412	0.227	CbGbCtD
Temozolomide—CYP3A4—Etoposide—testicular cancer	0.00371	0.205	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—testicular cancer	0.00253	0.14	CbGbCtD
Temozolomide—Hyperglycaemia—Doxorubicin—testicular cancer	4.31e-05	0.000451	CcSEcCtD
Temozolomide—Nausea—Dactinomycin—testicular cancer	4.3e-05	0.00045	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—testicular cancer	4.28e-05	0.000448	CcSEcCtD
Temozolomide—Gastrointestinal pain—Etoposide—testicular cancer	4.28e-05	0.000448	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—testicular cancer	4.26e-05	0.000446	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—testicular cancer	4.26e-05	0.000446	CcSEcCtD
Temozolomide—Visual impairment—Methotrexate—testicular cancer	4.25e-05	0.000445	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	4.22e-05	0.000442	CcSEcCtD
Temozolomide—Vomiting—Ifosfamide—testicular cancer	4.21e-05	0.000441	CcSEcCtD
Temozolomide—Hypersensitivity—Cisplatin—testicular cancer	4.21e-05	0.000441	CcSEcCtD
Temozolomide—Rash—Ifosfamide—testicular cancer	4.18e-05	0.000437	CcSEcCtD
Temozolomide—Dermatitis—Ifosfamide—testicular cancer	4.17e-05	0.000437	CcSEcCtD
Temozolomide—Erythema multiforme—Methotrexate—testicular cancer	4.17e-05	0.000437	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—testicular cancer	4.17e-05	0.000437	CcSEcCtD
Temozolomide—Urticaria—Etoposide—testicular cancer	4.16e-05	0.000435	CcSEcCtD
Temozolomide—Haemoglobin—Epirubicin—testicular cancer	4.15e-05	0.000434	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—testicular cancer	4.15e-05	0.000434	CcSEcCtD
Temozolomide—Body temperature increased—Etoposide—testicular cancer	4.14e-05	0.000433	CcSEcCtD
Temozolomide—Abdominal pain—Etoposide—testicular cancer	4.14e-05	0.000433	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—testicular cancer	4.14e-05	0.000433	CcSEcCtD
Temozolomide—Haemorrhage—Epirubicin—testicular cancer	4.13e-05	0.000432	CcSEcCtD
Temozolomide—Hepatitis—Epirubicin—testicular cancer	4.13e-05	0.000432	CcSEcCtD
Temozolomide—Eye disorder—Methotrexate—testicular cancer	4.12e-05	0.000432	CcSEcCtD
Temozolomide—Tinnitus—Methotrexate—testicular cancer	4.11e-05	0.000431	CcSEcCtD
Temozolomide—Hypoaesthesia—Epirubicin—testicular cancer	4.11e-05	0.00043	CcSEcCtD
Temozolomide—Asthenia—Cisplatin—testicular cancer	4.1e-05	0.000429	CcSEcCtD
Temozolomide—Pharyngitis—Epirubicin—testicular cancer	4.1e-05	0.000429	CcSEcCtD
Temozolomide—Cardiac disorder—Methotrexate—testicular cancer	4.1e-05	0.000429	CcSEcCtD
Temozolomide—Urinary tract disorder—Epirubicin—testicular cancer	4.08e-05	0.000427	CcSEcCtD
Temozolomide—Oedema peripheral—Epirubicin—testicular cancer	4.07e-05	0.000426	CcSEcCtD
Temozolomide—Connective tissue disorder—Epirubicin—testicular cancer	4.06e-05	0.000425	CcSEcCtD
Temozolomide—Urethral disorder—Epirubicin—testicular cancer	4.05e-05	0.000424	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—testicular cancer	4.03e-05	0.000421	CcSEcCtD
Temozolomide—Angiopathy—Methotrexate—testicular cancer	4e-05	0.000419	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—testicular cancer	3.99e-05	0.000418	CcSEcCtD
Temozolomide—Immune system disorder—Methotrexate—testicular cancer	3.99e-05	0.000417	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—testicular cancer	3.98e-05	0.000417	CcSEcCtD
Temozolomide—Mediastinal disorder—Methotrexate—testicular cancer	3.98e-05	0.000416	CcSEcCtD
Temozolomide—Chills—Methotrexate—testicular cancer	3.96e-05	0.000414	CcSEcCtD
Temozolomide—Nausea—Ifosfamide—testicular cancer	3.94e-05	0.000412	CcSEcCtD
Temozolomide—Diarrhoea—Cisplatin—testicular cancer	3.91e-05	0.000409	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—testicular cancer	3.9e-05	0.000409	CcSEcCtD
Temozolomide—Alopecia—Methotrexate—testicular cancer	3.9e-05	0.000408	CcSEcCtD
Temozolomide—Mental disorder—Methotrexate—testicular cancer	3.87e-05	0.000405	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—testicular cancer	3.86e-05	0.000404	CcSEcCtD
Temozolomide—Hypersensitivity—Etoposide—testicular cancer	3.86e-05	0.000404	CcSEcCtD
Temozolomide—Tinnitus—Epirubicin—testicular cancer	3.85e-05	0.000403	CcSEcCtD
Temozolomide—Malnutrition—Methotrexate—testicular cancer	3.84e-05	0.000402	CcSEcCtD
Temozolomide—Erythema—Methotrexate—testicular cancer	3.84e-05	0.000402	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—testicular cancer	3.84e-05	0.000402	CcSEcCtD
Temozolomide—Flushing—Epirubicin—testicular cancer	3.83e-05	0.000401	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—testicular cancer	3.83e-05	0.000401	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—testicular cancer	3.82e-05	0.0004	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—testicular cancer	3.82e-05	0.0004	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—testicular cancer	3.8e-05	0.000398	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—testicular cancer	3.79e-05	0.000397	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—testicular cancer	3.77e-05	0.000395	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—testicular cancer	3.76e-05	0.000394	CcSEcCtD
Temozolomide—Dysgeusia—Methotrexate—testicular cancer	3.76e-05	0.000394	CcSEcCtD
Temozolomide—Asthenia—Etoposide—testicular cancer	3.76e-05	0.000393	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—testicular cancer	3.75e-05	0.000393	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—testicular cancer	3.75e-05	0.000392	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—testicular cancer	3.75e-05	0.000392	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—testicular cancer	3.73e-05	0.00039	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—testicular cancer	3.72e-05	0.00039	CcSEcCtD
Temozolomide—Back pain—Methotrexate—testicular cancer	3.72e-05	0.000389	CcSEcCtD
Temozolomide—Chills—Epirubicin—testicular cancer	3.71e-05	0.000388	CcSEcCtD
Temozolomide—Pruritus—Etoposide—testicular cancer	3.7e-05	0.000388	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—testicular cancer	3.68e-05	0.000385	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—testicular cancer	3.65e-05	0.000382	CcSEcCtD
Temozolomide—Vomiting—Cisplatin—testicular cancer	3.63e-05	0.00038	CcSEcCtD
Temozolomide—Vision blurred—Methotrexate—testicular cancer	3.62e-05	0.000379	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—testicular cancer	3.62e-05	0.000379	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—testicular cancer	3.61e-05	0.000378	CcSEcCtD
Temozolomide—Rash—Cisplatin—testicular cancer	3.6e-05	0.000377	CcSEcCtD
Temozolomide—Dermatitis—Cisplatin—testicular cancer	3.6e-05	0.000377	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—testicular cancer	3.59e-05	0.000376	CcSEcCtD
Temozolomide—Erythema—Epirubicin—testicular cancer	3.59e-05	0.000376	CcSEcCtD
Temozolomide—Diarrhoea—Etoposide—testicular cancer	3.58e-05	0.000375	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—testicular cancer	3.57e-05	0.000374	CcSEcCtD
Temozolomide—Ill-defined disorder—Methotrexate—testicular cancer	3.56e-05	0.000373	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—testicular cancer	3.56e-05	0.000373	CcSEcCtD
Temozolomide—Anaemia—Methotrexate—testicular cancer	3.55e-05	0.000372	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—testicular cancer	3.55e-05	0.000371	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—testicular cancer	3.55e-05	0.000371	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—testicular cancer	3.52e-05	0.000368	CcSEcCtD
Temozolomide—Back pain—Epirubicin—testicular cancer	3.48e-05	0.000364	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—testicular cancer	3.47e-05	0.000363	CcSEcCtD
Temozolomide—Malaise—Methotrexate—testicular cancer	3.46e-05	0.000363	CcSEcCtD
Temozolomide—Dizziness—Etoposide—testicular cancer	3.46e-05	0.000362	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—testicular cancer	3.45e-05	0.000361	CcSEcCtD
Temozolomide—Vertigo—Methotrexate—testicular cancer	3.45e-05	0.000361	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—testicular cancer	3.44e-05	0.00036	CcSEcCtD
Temozolomide—Leukopenia—Methotrexate—testicular cancer	3.44e-05	0.00036	CcSEcCtD
Temozolomide—Chills—Doxorubicin—testicular cancer	3.43e-05	0.000359	CcSEcCtD
Temozolomide—Nausea—Cisplatin—testicular cancer	3.39e-05	0.000355	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—testicular cancer	3.39e-05	0.000355	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—testicular cancer	3.38e-05	0.000353	CcSEcCtD
Temozolomide—Cough—Methotrexate—testicular cancer	3.35e-05	0.000351	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—testicular cancer	3.35e-05	0.00035	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—testicular cancer	3.34e-05	0.000349	CcSEcCtD
Temozolomide—Convulsion—Methotrexate—testicular cancer	3.33e-05	0.000348	CcSEcCtD
Temozolomide—Vomiting—Etoposide—testicular cancer	3.33e-05	0.000348	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—testicular cancer	3.33e-05	0.000348	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—testicular cancer	3.33e-05	0.000348	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—testicular cancer	3.32e-05	0.000348	CcSEcCtD
Temozolomide—Agitation—Epirubicin—testicular cancer	3.3e-05	0.000346	CcSEcCtD
Temozolomide—Rash—Etoposide—testicular cancer	3.3e-05	0.000345	CcSEcCtD
Temozolomide—Dermatitis—Etoposide—testicular cancer	3.3e-05	0.000345	CcSEcCtD
Temozolomide—Headache—Etoposide—testicular cancer	3.28e-05	0.000343	CcSEcCtD
Temozolomide—Arthralgia—Methotrexate—testicular cancer	3.27e-05	0.000342	CcSEcCtD
Temozolomide—Myalgia—Methotrexate—testicular cancer	3.27e-05	0.000342	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—testicular cancer	3.26e-05	0.000341	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	3.25e-05	0.00034	CcSEcCtD
Temozolomide—Malaise—Epirubicin—testicular cancer	3.24e-05	0.000339	CcSEcCtD
Temozolomide—Discomfort—Methotrexate—testicular cancer	3.23e-05	0.000338	CcSEcCtD
Temozolomide—Vertigo—Epirubicin—testicular cancer	3.23e-05	0.000338	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—testicular cancer	3.22e-05	0.000337	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—testicular cancer	3.22e-05	0.000337	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—testicular cancer	3.18e-05	0.000333	CcSEcCtD
Temozolomide—Confusional state—Methotrexate—testicular cancer	3.16e-05	0.000331	CcSEcCtD
Temozolomide—Cough—Epirubicin—testicular cancer	3.14e-05	0.000328	CcSEcCtD
Temozolomide—Anaphylactic shock—Methotrexate—testicular cancer	3.14e-05	0.000328	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—testicular cancer	3.13e-05	0.000328	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—testicular cancer	3.11e-05	0.000326	CcSEcCtD
Temozolomide—Infection—Methotrexate—testicular cancer	3.11e-05	0.000326	CcSEcCtD
Temozolomide—Nausea—Etoposide—testicular cancer	3.11e-05	0.000325	CcSEcCtD
Temozolomide—Hypertension—Epirubicin—testicular cancer	3.1e-05	0.000325	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—testicular cancer	3.09e-05	0.000323	CcSEcCtD
Temozolomide—Nervous system disorder—Methotrexate—testicular cancer	3.07e-05	0.000322	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—testicular cancer	3.07e-05	0.000322	CcSEcCtD
Temozolomide—Thrombocytopenia—Methotrexate—testicular cancer	3.07e-05	0.000321	CcSEcCtD
Temozolomide—Arthralgia—Epirubicin—testicular cancer	3.06e-05	0.00032	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—testicular cancer	3.06e-05	0.00032	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—testicular cancer	3.06e-05	0.00032	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—testicular cancer	3.05e-05	0.000319	CcSEcCtD
Temozolomide—Skin disorder—Methotrexate—testicular cancer	3.05e-05	0.000319	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.04e-05	0.000318	CcSEcCtD
Temozolomide—Hyperhidrosis—Methotrexate—testicular cancer	3.03e-05	0.000317	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—testicular cancer	3.02e-05	0.000316	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—testicular cancer	3e-05	0.000314	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—testicular cancer	2.99e-05	0.000313	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—testicular cancer	2.99e-05	0.000313	CcSEcCtD
Temozolomide—Anorexia—Methotrexate—testicular cancer	2.99e-05	0.000313	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—testicular cancer	2.98e-05	0.000312	CcSEcCtD
Temozolomide—Confusional state—Epirubicin—testicular cancer	2.96e-05	0.00031	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—testicular cancer	2.94e-05	0.000308	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—testicular cancer	2.93e-05	0.000307	CcSEcCtD
Temozolomide—Oedema—Epirubicin—testicular cancer	2.93e-05	0.000307	CcSEcCtD
Temozolomide—Infection—Epirubicin—testicular cancer	2.91e-05	0.000305	CcSEcCtD
Temozolomide—Cough—Doxorubicin—testicular cancer	2.9e-05	0.000304	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—testicular cancer	2.88e-05	0.000302	CcSEcCtD
Temozolomide—Nervous system disorder—Epirubicin—testicular cancer	2.88e-05	0.000301	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—testicular cancer	2.87e-05	0.000301	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—testicular cancer	2.87e-05	0.000301	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Methotrexate—testicular cancer	2.86e-05	0.000299	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—testicular cancer	2.85e-05	0.000298	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—testicular cancer	2.84e-05	0.000297	CcSEcCtD
Temozolomide—Insomnia—Methotrexate—testicular cancer	2.84e-05	0.000297	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—testicular cancer	2.83e-05	0.000296	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—testicular cancer	2.83e-05	0.000296	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—testicular cancer	2.82e-05	0.000295	CcSEcCtD
Temozolomide—Paraesthesia—Methotrexate—testicular cancer	2.82e-05	0.000295	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.81e-05	0.000294	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—testicular cancer	2.8e-05	0.000293	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—testicular cancer	2.8e-05	0.000293	CcSEcCtD
Temozolomide—Dyspnoea—Methotrexate—testicular cancer	2.8e-05	0.000293	CcSEcCtD
Temozolomide—Somnolence—Methotrexate—testicular cancer	2.79e-05	0.000292	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—testicular cancer	2.77e-05	0.00029	CcSEcCtD
Temozolomide—Dyspepsia—Methotrexate—testicular cancer	2.76e-05	0.000289	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—testicular cancer	2.74e-05	0.000287	CcSEcCtD
Temozolomide—Decreased appetite—Methotrexate—testicular cancer	2.73e-05	0.000285	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—testicular cancer	2.71e-05	0.000284	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—testicular cancer	2.71e-05	0.000284	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Methotrexate—testicular cancer	2.71e-05	0.000283	CcSEcCtD
Temozolomide—Fatigue—Methotrexate—testicular cancer	2.7e-05	0.000283	CcSEcCtD
Temozolomide—Infection—Doxorubicin—testicular cancer	2.7e-05	0.000282	CcSEcCtD
Temozolomide—Pain—Methotrexate—testicular cancer	2.68e-05	0.000281	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.67e-05	0.00028	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—testicular cancer	2.66e-05	0.000279	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—testicular cancer	2.66e-05	0.000278	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—testicular cancer	2.65e-05	0.000278	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—testicular cancer	2.64e-05	0.000276	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—testicular cancer	2.63e-05	0.000276	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—testicular cancer	2.62e-05	0.000275	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—testicular cancer	2.62e-05	0.000274	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—testicular cancer	2.61e-05	0.000273	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—testicular cancer	2.59e-05	0.000271	CcSEcCtD
Temozolomide—Feeling abnormal—Methotrexate—testicular cancer	2.58e-05	0.00027	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—testicular cancer	2.58e-05	0.00027	CcSEcCtD
Temozolomide—Gastrointestinal pain—Methotrexate—testicular cancer	2.56e-05	0.000268	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—testicular cancer	2.55e-05	0.000267	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—testicular cancer	2.53e-05	0.000265	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—testicular cancer	2.53e-05	0.000265	CcSEcCtD
Temozolomide—Pain—Epirubicin—testicular cancer	2.51e-05	0.000263	CcSEcCtD
Temozolomide—Constipation—Epirubicin—testicular cancer	2.51e-05	0.000263	CcSEcCtD
Temozolomide—Urticaria—Methotrexate—testicular cancer	2.49e-05	0.000261	CcSEcCtD
Temozolomide—Abdominal pain—Methotrexate—testicular cancer	2.48e-05	0.000259	CcSEcCtD
Temozolomide—Body temperature increased—Methotrexate—testicular cancer	2.48e-05	0.000259	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.47e-05	0.000259	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—testicular cancer	2.46e-05	0.000257	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—testicular cancer	2.44e-05	0.000255	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—testicular cancer	2.42e-05	0.000253	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—testicular cancer	2.42e-05	0.000253	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—testicular cancer	2.41e-05	0.000253	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—testicular cancer	2.4e-05	0.000251	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—testicular cancer	2.39e-05	0.00025	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—testicular cancer	2.36e-05	0.000247	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.34e-05	0.000245	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—testicular cancer	2.34e-05	0.000245	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—testicular cancer	2.33e-05	0.000244	CcSEcCtD
Temozolomide—Pain—Doxorubicin—testicular cancer	2.32e-05	0.000243	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—testicular cancer	2.32e-05	0.000243	CcSEcCtD
Temozolomide—Abdominal pain—Epirubicin—testicular cancer	2.32e-05	0.000243	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—testicular cancer	2.32e-05	0.000243	CcSEcCtD
Temozolomide—Hypersensitivity—Methotrexate—testicular cancer	2.31e-05	0.000242	CcSEcCtD
Temozolomide—Asthenia—Methotrexate—testicular cancer	2.25e-05	0.000235	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—testicular cancer	2.24e-05	0.000234	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—testicular cancer	2.22e-05	0.000232	CcSEcCtD
Temozolomide—Pruritus—Methotrexate—testicular cancer	2.22e-05	0.000232	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—testicular cancer	2.16e-05	0.000226	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—testicular cancer	2.16e-05	0.000226	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—testicular cancer	2.15e-05	0.000225	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—testicular cancer	2.15e-05	0.000225	CcSEcCtD
Temozolomide—Diarrhoea—Methotrexate—testicular cancer	2.15e-05	0.000225	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—testicular cancer	2.11e-05	0.00022	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—testicular cancer	2.08e-05	0.000217	CcSEcCtD
Temozolomide—Dizziness—Methotrexate—testicular cancer	2.07e-05	0.000217	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—testicular cancer	2.01e-05	0.00021	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—testicular cancer	2e-05	0.000209	CcSEcCtD
Temozolomide—Vomiting—Methotrexate—testicular cancer	1.99e-05	0.000209	CcSEcCtD
Temozolomide—Rash—Methotrexate—testicular cancer	1.98e-05	0.000207	CcSEcCtD
Temozolomide—Dermatitis—Methotrexate—testicular cancer	1.97e-05	0.000207	CcSEcCtD
Temozolomide—Headache—Methotrexate—testicular cancer	1.96e-05	0.000206	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—testicular cancer	1.95e-05	0.000204	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—testicular cancer	1.94e-05	0.000203	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—testicular cancer	1.92e-05	0.000201	CcSEcCtD
Temozolomide—Vomiting—Epirubicin—testicular cancer	1.87e-05	0.000195	CcSEcCtD
Temozolomide—Nausea—Methotrexate—testicular cancer	1.86e-05	0.000195	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—testicular cancer	1.86e-05	0.000194	CcSEcCtD
Temozolomide—Rash—Epirubicin—testicular cancer	1.85e-05	0.000194	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—testicular cancer	1.85e-05	0.000193	CcSEcCtD
Temozolomide—Headache—Epirubicin—testicular cancer	1.84e-05	0.000192	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—testicular cancer	1.8e-05	0.000188	CcSEcCtD
Temozolomide—Nausea—Epirubicin—testicular cancer	1.74e-05	0.000182	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—testicular cancer	1.73e-05	0.000181	CcSEcCtD
Temozolomide—Rash—Doxorubicin—testicular cancer	1.71e-05	0.000179	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—testicular cancer	1.71e-05	0.000179	CcSEcCtD
Temozolomide—Headache—Doxorubicin—testicular cancer	1.7e-05	0.000178	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—testicular cancer	1.61e-05	0.000169	CcSEcCtD
